Transcriptional consequences of autosomal trisomy: primary gene dosage with complex downstream effects.

Autosomal trisomy is a common cause of human miscarriage, malformations and learning disability. Primary gene-dosage effects have been confirmed by recent transcriptome analyses. The importance (or existence) of trans-acting effects on disomic genes remains, surprisingly, controversial. In this article, I propose a model of the main genetic mechanisms that are responsible for producing the transcriptional derangement associated with trisomy. This has implications for future study design.

[1]  J. Birchler,et al.  Dosage-dependent gene regulation in multicellular eukaryotes: implications for dosage compensation, aneuploid syndromes, and quantitative traits. , 2001, Developmental biology.

[2]  Katheleen Gardiner,et al.  Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. , 2003, Gene.

[3]  R. Behringer,et al.  Tetraploid development in the mouse , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.

[4]  L. Personnaz,et al.  The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. , 2005, Human molecular genetics.

[5]  R. Reeves,et al.  Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. , 2003, Human molecular genetics.

[6]  S. South,et al.  Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. , 2004, Genome research.

[7]  N. Hastie,et al.  Transcriptome analysis of human autosomal trisomy. , 2002, Human molecular genetics.

[8]  K. Spencer,et al.  First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defects , 1993, Prenatal diagnosis.

[9]  Joan T Richtsmeier,et al.  Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. , 2002, American journal of medical genetics.

[10]  M. Petersen,et al.  Nondisjunction in trisomy 21: Origin and mechanisms , 2001, Cytogenetic and Genome Research.

[11]  K. Yamakawa,et al.  Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. , 2004, Human molecular genetics.

[12]  C. Epstein,et al.  Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Jacobs,et al.  A cytogenetic study of 1000 spontaneous abortions , 1980, Annals of human genetics.

[14]  Stylianos E. Antonarakis,et al.  Chromosome 21 and Down syndrome: from genomics to pathophysiology , 2004, Nature Reviews Genetics.

[15]  A. Hackshaw,et al.  Revised distribution parameters for serum markers for trisomy 18 , 2000, Journal of Medical Screening.

[16]  Yang Liu,et al.  Mouse Brain Organization Revealed Through Direct Genome-Scale TF Expression Analysis , 2004, Science.

[17]  R. Bronson,et al.  A mouse model for Down syndrome exhibits learning and behaviour deficits , 1995, Nature Genetics.

[18]  C. Cooke‐Yarborough,et al.  Karyotype, phenotype and parental origin in 19 cases of triploidy , 2001, Prenatal diagnosis.

[19]  J T Richtsmeier,et al.  Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. , 2000, Human molecular genetics.

[20]  S. Antonarakis,et al.  Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. , 2004, Genome research.

[21]  J. Birchler,et al.  Dosage effects on gene expression in a maize ploidy series. , 1996, Genetics.

[22]  Jonathan Pevsner,et al.  Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. , 2003, Genomics.